DOJ Signals Faster, More Aggressive Handling of Certain False Claims Act Investigations

The U.S. Department of Justice (DOJ) recently announced a significant policy shift that could have major implications for healthcare providers. In a memo issued by the DOJ’s Civil Division on May 27, 2026, DOJ directed its attorneys to accelerate the review and investigation of FCA cases involving alleged benefits fraud. The DOJ’s memo signals a more aggressive enforcement posture and a desire to move these matters through the investigative process much more quickly than in the past.

Faster Decisions in Qui Tam Cases

Under the new guidance, DOJ attorneys are instructed to review newly filed whistleblower, or qui tam, cases involving benefits fraud on an expedited timeline. The memo states that, where practicable, the DOJ should complete its initial review within 60 days and, in most cases, no later than 120 days. At the conclusion of that review period, DOJ is expected to decide whether to intervene in the case, continue investigating, allow the relator to proceed independently, or seek dismissal if the allegations lack merit.

For defendants, this development is noteworthy because FCA investigations have traditionally remained under seal for extended periods (often many years) while the government conducted lengthy investigations. The new policy suggests that many cases may move toward critical decision points much sooner.

More Aggressive Investigative Tools

The memo also directs DOJ attorneys to pursue investigations more efficiently once a case is opened. Among other things, DOJ personnel are encouraged to:

• Develop investigative plans early in the process;
• Promptly issue Civil Investigative Demands (CIDs) and subpoenas;
• Conduct witness interviews at the outset of investigations;
• Narrow requests to focus on the most relevant evidence; and
• Enforce subpoenas and CIDs when recipients fail to comply without adequate justification.

These directives suggest that organizations facing FCA scrutiny should expect government requests to arrive sooner and with shorter response windows than they may have encountered in prior investigations.

Increased Risk of Parallel Proceedings

The DOJ memo also emphasizes coordination with other enforcement authorities. The memo provides that new benefits-fraud matters should be referred promptly to criminal prosecutors and appropriate enforcement components for evaluation of potential criminal violations. The memo also contemplates referrals to agencies for administrative remedies, including payment suspensions and other enforcement actions.

For healthcare providers, that means an investigation could potentially implicate reimbursement, licensing, exclusion, credentialing, and criminal enforcement concerns all at once.

Looking Ahead

Although the memo primarily addresses the DOJ’s internal handling of benefits-fraud matters, its message is clear: the DOJ intends to identify, evaluate, and pursue these cases more quickly than before.

Healthcare providers participating in Medicare, Medicaid, and other federal healthcare programs should expect closer scrutiny, faster investigative timelines, and increased coordination among civil, criminal, and administrative enforcement authorities. In this environment, early assessment and strategic response may be more important than ever.

GWB represents healthcare providers in connection with government investigations and False Claims Act litigation. If you need assistance with such a matter, contact us today.